Does aldosterone predict incident cardiovascular, renal, and metabolic disease in the general community?
Aldosterone levels predict the development of cardiometabolic and renal diseases, including hypertension, diabetes, and CKD, over a 4-year period in the general community.
Aldosterone predicts new HTN, central obesity, T2DM, and use of lipid-lowering drugs in the general community and remains associated with HTN, obesity, and CKD over 4 years. Aldosterone is not associated nor predicts HF. Further studies are warranted to evaluate aldosterone as therapeutic target in the general community.
Buglioni et al. (Tue,) studied this question.